Literature DB >> 25832603

Approach to chemotherapy-associated thrombosis.

Peter Oppelt1, Anthony Betbadal2, Lalitha Nayak2.   

Abstract

Treatment of cancer patients with antineoplastic agents is associated with a heightened risk of thrombotic events, both arterial and venous. In this article, we review the specific agents that are implicated and the pathophysiological processes that are known to be associated with this prothrombotic state. We conclude with current recommendations for prophylactic antithrombotic therapy in these clinical situations.
© The Author(s) 2015.

Entities:  

Keywords:  angiogenesis inhibitors; anticoagulants; endothelial cells; pulmonary embolism; review; thromboembolism; thrombosis; venous thrombosis

Mesh：

Substances：

Year:  2015        PMID： 25832603      PMCID： PMC4655120          DOI： 10.1177/1358863X14568705

Source DB:  PubMed          Journal:  Vasc Med        ISSN： 1358-863X            Impact factor:   3.239


  101 in total

1.  PRODIGE: a randomized placebo-controlled trial of dalteparin low-molecular-weight heparin thromboprophylaxis in patients with newly diagnosed malignant glioma.

Authors:  J R Perry; J A Julian; N J Laperriere; W Geerts; G Agnelli; L R Rogers; M G Malkin; R Sawaya; R Baker; A Falanga; S Parpia; T Finch; M N Levine
Journal:  J Thromb Haemost       Date:  2010-09       Impact factor: 5.824

Review 2.  Erythropoietin or darbepoetin for patients with cancer.

Authors:  Thomy Tonia; Annette Mettler; Nadège Robert; Guido Schwarzer; Jerome Seidenfeld; Olaf Weingart; Chris Hyde; Andreas Engert; Julia Bohlius
Journal:  Cochrane Database Syst Rev       Date:  2012-12-12

3.  Multiple myeloma, venous thromboembolism, and treatment-related risk of thrombosis.

Authors:  Elena Zamagni; Annamaria Brioli; Paola Tacchetti; Beatrice Zannetti; Lucia Pantani; Michele Cavo
Journal:  Semin Thromb Hemost       Date:  2011-03-31       Impact factor: 4.180

4.  Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma.

Authors:  S A Schey; P Fields; J B Bartlett; I A Clarke; G Ashan; R D Knight; M Streetly; A G Dalgleish
Journal:  J Clin Oncol       Date:  2004-07-12       Impact factor: 44.544

5.  Effect of disease and chemotherapy on hemostasis in children with acute lymphoid leukemia.

Authors:  L G Mitchell; J M Halton; P A Vegh; R D Barr; T Venneri; K M Pai; M E Andrew
Journal:  Am J Pediatr Hematol Oncol       Date:  1994-05

6.  Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study.

Authors:  Paul G Richardson; David S Siegel; Ravi Vij; Craig C Hofmeister; Rachid Baz; Sundar Jagannath; Christine Chen; Sagar Lonial; Andrzej Jakubowiak; Nizar Bahlis; Kevin Song; Andrew Belch; Noopur Raje; Chaim Shustik; Suzanne Lentzsch; Martha Lacy; Joseph Mikhael; Jeffrey Matous; David Vesole; Min Chen; Mohamed H Zaki; Christian Jacques; Zhinuan Yu; Kenneth C Anderson
Journal:  Blood       Date:  2014-01-13       Impact factor: 22.113

7.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

Authors:  Herbert Hurwitz; Louis Fehrenbacher; William Novotny; Thomas Cartwright; John Hainsworth; William Heim; Jordan Berlin; Ari Baron; Susan Griffing; Eric Holmgren; Napoleone Ferrara; Gwen Fyfe; Beth Rogers; Robert Ross; Fairooz Kabbinavar
Journal:  N Engl J Med       Date:  2004-06-03       Impact factor: 91.245

8.  Capecitabine and oxaliplatin for advanced esophagogastric cancer.

Authors:  David Cunningham; Naureen Starling; Sheela Rao; Timothy Iveson; Marianne Nicolson; Fareeda Coxon; Gary Middleton; Francis Daniel; Jacqueline Oates; Andrew Richard Norman
Journal:  N Engl J Med       Date:  2008-01-03       Impact factor: 91.245

9.  Thalidomide alone or with dexamethasone for previously untreated multiple myeloma.

Authors:  Donna Weber; Kim Rankin; Maria Gavino; Kay Delasalle; Raymond Alexanian
Journal:  J Clin Oncol       Date:  2003-01-01       Impact factor: 44.544

10.  Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study.

Authors:  Giancarlo Agnelli; Gualberto Gussoni; Carlo Bianchini; Melina Verso; Mario Mandalà; Luigi Cavanna; Sandro Barni; Roberto Labianca; Franco Buzzi; Giovanni Scambia; Rodolfo Passalacqua; Sergio Ricci; Giampietro Gasparini; Vito Lorusso; Erminio Bonizzoni; Maurizio Tonato
Journal:  Lancet Oncol       Date:  2009-08-31       Impact factor: 41.316
View more
  11 in total

1.  Anticoagulation and bleeding in the cancer patient.

Authors:  Andres Escobar; Ahmed M Salem; Kodwo Dickson; Tami N Johnson; Kathyrn J Burk; Lara Bashoura; Saadia A Faiz
Journal:  Support Care Cancer       Date:  2022-05-17       Impact factor: 3.359

2.  VEGFR3 tyrosine kinase inhibition aggravates cisplatin nephrotoxicity.

Authors:  Laurence M Black; Elisa R Farrell; Daria Barwinska; Gunars Osis; Anna A Zmijewska; Amie M Traylor; Stephanie K Esman; Subhashini Bolisetty; Grace Whipple; Malgorzata M Kamocka; Seth Winfree; Daryll R Spangler; Shehnaz Khan; Abolfazl Zarjou; Tarek M El-Achkar; Anupam Agarwal
Journal:  Am J Physiol Renal Physiol       Date:  2021-10-18

3.  Venous thromboembolism after esophagectomy for cancer: a systematic review of the literature to evaluate incidence, risk factors, and prophylaxis.

Authors:  Nikoletta A Theochari; Christina A Theochari; Damianos G Kokkinidis; Aristotelis Kechagias; Orestis Lyros; Stefanos Giannopoulos; Styliani Mantziari; Dimitrios Schizas
Journal:  Surg Today       Date:  2021-03-13       Impact factor: 2.549

4.  [Tissue factors and venous thromboembolism in cancer patients].

Authors:  Huiqi Zhu; Kejing Ying
Journal:  Zhejiang Da Xue Xue Bao Yi Xue Ban       Date:  2020-12-25

5.  Can thromboprophylaxis build a link for cancer patients undergoing surgical and/or chemotherapy treatment? The MeTHOS cohort study.

Authors:  Spyridon Xynogalos; David Simeonidis; George Papageorgiou; Abraham Pouliakis; Nikolaos Charalambakis; Evangelos Lianos; Evridiki Mazlimoglou; Alexandros-Nikolaos Liatsos; Christos Kosmas; Nicolaos Ziras
Journal:  Support Care Cancer       Date:  2022-05-12       Impact factor: 3.359

Review 6.  Vascular toxicities with VEGF inhibitor therapies-focus on hypertension and arterial thrombotic events.

Authors:  Rhian M Touyz; Sandra M S Herrmann; Joerg Herrmann
Journal:  J Am Soc Hypertens       Date:  2018-03-21

Review 7.  VEGF-A in Cardiomyocytes and Heart Diseases.

Authors:  Mariantonia Braile; Simone Marcella; Leonardo Cristinziano; Maria Rosaria Galdiero; Luca Modestino; Anne Lise Ferrara; Gilda Varricchi; Giancarlo Marone; Stefania Loffredo
Journal:  Int J Mol Sci       Date:  2020-07-26       Impact factor: 5.923

8.  Central Venous Catheter Thrombosis in Cancer: A Multi-Centre Retrospective Study Investigating Risk Factors and Contemporary Trends in Management.

Authors:  Lucy Haggstrom; Gurdeep Parmar; Daniel Brungs
Journal:  Clin Med Insights Oncol       Date:  2020-08-30

9.  Prophylaxis of cancer-associated venous thromboembolism with low-molecular-weight heparin-tinzaparin: Real world evidence.

Authors:  Athina Christopoulou; Alexandros Ardavanis; Christos Papandreou; Georgios Koumakis; Georgios Papatsimpas; Pavlos Papakotoulas; Nikolaos Tsoukalas; Charalambos Andreadis; Georgios Samelis; Pavlos Papakostas; Gerasimos Aravantinos; Nikolaos Ziras; Maria Souggleri; Charalambos Kalofonos; Epameinondas Samantas; Paris Makrantonakis; Georgios Pentheroudakis; Athanasios Athanasiadis; Helen Stergiou; Alexandros Bokas; Anastasios Grivas; Elli-Sofia Tripodaki; Ioannis Varthalitis; Eleni Timotheadou; Ioannis Boukovinas
Journal:  Oncol Lett       Date:  2022-02-09       Impact factor: 2.967

Review 10.  Cancer Therapy-Associated Thrombosis.

Authors:  Steven P Grover; Yohei M Hisada; Raj S Kasthuri; Brandi N Reeves; Nigel Mackman
Journal:  Arterioscler Thromb Vasc Biol       Date:  2021-02-11       Impact factor: 8.311
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.